
Immatics NV (IMTX) Stock Forecast & Price Target
Immatics NV (IMTX) Analyst Ratings
Bulls say
Immatics NV is making significant advancements in T-cell redirecting immunotherapies, particularly with its anzu-cel asset, which targets a high-unmet need market for metastatic cancers, presenting a substantial revenue opportunity estimated at $2 billion in the U.S. The company's innovative ACTengine platform enhances treatment logistics and has demonstrated strong manufacturing efficiency with a 98% success rate in Phase 1b, promising quicker product availability. Furthermore, the positive early data and the support from FDA's RMAT designation position Immatics favorably for potential success in its ongoing pivotal SUPRAME study, reinforcing a positive outlook for the company's financial performance.
Bears say
Immatics NV faces a negative outlook primarily due to underwhelming clinical data, specifically the 11% Overall Response Rate (ORR) and 56% Disease Control Rate (DCR) observed in Brenetafusp during ASCO '24, which may lead to downward revisions in risk-adjusted projections. The company is also exposed to multiple risks, including potential R&D setbacks, regulatory challenges, and the emergence of new competitors, which could further impact product sales adversely. Additionally, a downside scenario predicts a valuation drop to approximately $3 per share if critical milestones, such as those related to the SUPRAME study and early pipeline developments, are not met.
This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.
Immatics NV (IMTX) Analyst Forecast & Price Prediction
Start investing in Immatics NV (IMTX)
Order type
Buy in
Order amount
Est. shares
0 shares